2
|
Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, Nishino M, Weinblatt ME, Ascherman DP, Washko GR, Hunninghake GM, Choi AMK, Shadick NA, Rosas IO. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest 2014; 146:41-50. [PMID: 24305643 DOI: 10.1378/chest.13-1394] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Approximately 10% of patients with rheumatoid arthritis (RA) have interstitial lung disease (ILD), and one-third have subclinical ILD on chest CT scan. In this study, we aimed to further characterize functional decrements in a spectrum of RA-associated ILD. METHODS All subjects were enrolled in the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS). The presence of interstitial lung abnormalities (ILAs) on clinically indicated chest CT scans was determined using a previously validated sequential reading method. Univariate and multivariate analyses were used to assess the association between degree of ILAs and physiologic, functional, and demographic variables of interest. RESULTS Of 1,145 BRASS subjects, 91 subjects (8%) were included in this study. Twelve had radiologically severe ILAs, 34 had ILAs, and 38 had no ILAs on CT scan. Subjects with radiologically severe ILAs were older (P = .0037), had increased respiratory symptoms (cough, P = .027; dyspnea, P = .010), and more severe RA disease (rheumatoid factor, P = .018; total swollen joints, P = .046) compared with subjects with no ILAs. Participants also had a trend toward having an increased smoking history (P = .16) and having lower FVC % predicted (77% vs 94%, P = .097) and diffusion capacity of carbon monoxide % predicted (52% vs 77%, P = .068). Similar but attenuated increases in respiratory symptoms, functional decrements, and RA disease severity were observed in subjects with ILAs compared with those with no ILAs. CONCLUSIONS We have shown that patients with RA have varying degrees of ILAs that are associated with a spectrum of functional and physiologic decrements. Our findings suggest that improved risk stratification and detection of ILAs will provide a therapeutic window that could improve RA-ILD outcomes.
Collapse
Affiliation(s)
- Tracy J Doyle
- Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Paul F Dellaripa
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
| | - Kerri Batra
- Division of Rheumatology, Rhode Island Hospital, Providence RI
| | - Michelle L Frits
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
| | - Christine K Iannaccone
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
| | - Hiroto Hatabu
- Center for Pulmonary Functional Imaging, Brigham and Women's Hospital, Boston, MA; Department of Radiology, Brigham and Women's Hospital, Boston, MA
| | - Mizuki Nishino
- Center for Pulmonary Functional Imaging, Brigham and Women's Hospital, Boston, MA; Department of Radiology, Brigham and Women's Hospital, Boston, MA
| | - Michael E Weinblatt
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
| | - Dana P Ascherman
- Division of Rheumatology, University of Miami Miller School of Medicine, Miami FL
| | - George R Washko
- Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Gary M Hunninghake
- Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Channing Laboratory, Brigham and Women's Hospital, Boston, MA
| | - Augustine M K Choi
- Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Nancy A Shadick
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
| | - Ivan O Rosas
- Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Lovelace Respiratory Research Institute, Albuquerque, NM.
| |
Collapse
|
3
|
Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 2014; 53:1676-82. [PMID: 24758887 DOI: 10.1093/rheumatology/keu165] [Citation(s) in RCA: 352] [Impact Index Per Article: 35.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVES The prevalence of interstitial lung disease (ILD) in RA is ∼5%. Previous work identified increasing age, active articular disease and articular damage as risk factors for RA-associated ILD (RA-ILD). The roles of high-resolution CT (HRCT) and lung function testing in defining the nature and extent of pulmonary involvement have recently been explored. This study is the first to examine predictive and prognostic factors for the development of RA-ILD and to report on the physiological and radiological characteristics of the condition from a large multicentre UK network. METHODS We collected data from centres across the UK on patients with both RA and ILD (proved on HRCT) diagnosed over a 25-year period from 1987 to 2012 using a standard pro forma. Potential predictors of RA-ILD were analysed. Baseline lung function data were recorded and related to HRCT findings. We analysed HRCT for subtype and extent of lung involved and examined the relationship between these and both all-cause and pulmonary mortality. We compared our results with case controls matched for age and gender using computer-generated selection from the RA population from one contributing centre. RESULTS A total of 230 patients were identified from across the UK with proven RA-ILD diagnosed over 25 years. Median age at diagnosis was 64 years and the male:female ratio was 1:1.09. Univariate analysis showed anti-CCP antibody titres to be the single most strongly associated predictor of RA-ILD. Male gender, age at onset, smoking and RF were all independently associated with RA-ILD on multivariate analysis. Vital capacity (VC) was preserved in limited disease but reduced in extensive disease, while gas transfer was reduced in both. Usual interstitial pneumonia (UIP) was the most common subtype on HRCT and both this and extensive disease were associated with increased all-cause mortality. CONCLUSION This is the largest study of RA-ILD in the UK. Anti-CCP antibodies were strongly associated with RA-ILD in both sexes. Smoking was strongly associated with ILD in males, which may explain the higher frequency of RA-ILD in men. The predominant HRCT pattern was UIP and most patients had limited disease at presentation. The presence of UIP and extensive disease are associated with increased mortality. Baseline gas transfer is a useful screening tool for ILD, while the preservation of VC at baseline might predict limited disease on HRCT.
Collapse
Affiliation(s)
- Clive A Kelly
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK.
| | - Vadivelu Saravanan
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Mohamed Nisar
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Subha Arthanari
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Felix A Woodhead
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Alec N Price-Forbes
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Julie Dawson
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Navtej Sathi
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Yasmeen Ahmad
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Gouri Koduri
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | - Adam Young
- Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, Department of Rheumatology, Burton Hospital, Burton on Trent, Department of Chest Medicine, Coventry and Warwickshire Hospital, Coventry, Department of Rheumatology, St Helens Hospital, Department of Rheumatology, Wrightington Hospital, St Helens, Department of Rheumatology, Betsi Cadwaldr University Health Board, Llandudno and Department of Rheumatology, St Albans City Hospital, St Albans, UK
| | | |
Collapse
|
4
|
Doyle TJ, Lee JS, Dellaripa PF, Lederer JA, Matteson EL, Fischer A, Ascherman DP, Glassberg MK, Ryu JH, Danoff SK, Brown KK, Collard HR, Rosas IO. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 2014; 145:454-463. [PMID: 24590021 DOI: 10.1378/chest.13-2408] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Rheumatoid arthritis (RA) is a systemic inflammatory disorder affecting approximately 1.3 million adults in the United States. Approximately 10% of these individuals with RA have clinically evident interstitial lung disease (RA-ILD), and an additional one-third demonstrate subclinical ILD on chest CT scan. The risk of death for individuals with RA-ILD is three times higher than for patients with RA without ILD, with a median survival after ILD diagnosis of only 2.6 years. Despite the high prevalence and mortality of RA-ILD, little is known about its molecular features and its natural history. At present, we lack a standard validated approach to the definition, diagnosis, risk stratification, and management of RA-ILD. In this perspective, we discuss the importance of clinical and translational research and how ongoing research efforts can address important gaps in our knowledge over the next few years. Furthermore, recommendations are made to design multicenter collaborative studies that will expedite the development of clinical trials designed to decrease the significant morbidity and mortality associated with RA-ILD.
Collapse
Affiliation(s)
- Tracy J Doyle
- Division of Pulmonary and Critical Care Medicine Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Joyce S Lee
- Division of Pulmonary and Critical Care Medicine, University of California San Francisco School of Medicine, San Francisco, CA
| | - Paul F Dellaripa
- Division of Rheumatology, Immunology, and Allergy Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - James A Lederer
- Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Eric L Matteson
- Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
| | - Aryeh Fischer
- Division of Rheumatology, National Jewish Health and University of Colorado, Denver, CO
| | - Dana P Ascherman
- Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL
| | - Marilyn K Glassberg
- Division of Pulmonary Medicine, University of Miami Miller School of Medicine, Miami, FL
| | - Jay H Ryu
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN
| | - Sonye K Danoff
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Kevin K Brown
- Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO
| | - Harold R Collard
- Division of Pulmonary and Critical Care Medicine, University of California San Francisco School of Medicine, San Francisco, CA
| | - Ivan O Rosas
- Lovelace Respiratory Research Institute, Albuquerque, NM.
| |
Collapse
|